CMTA-STAR Awards $1.1 Million for CMT1X, CMT2A Clinical Trials
CMTA-STAR announced $1.1 million in grants March 23 aimed at helping top CMT scientists prepare for clinical trials for CMT1X and CMT2A
CMTA and Pharnext Enter Biomarker Research Collaboration
Collaboration focused on identifying and characterizing key biomarkers
in Charcot-Marie-Tooth disease Type 1A
Type 2 Update: One Patient’s Diagnostic Odyssey with SORD
In "A Diagnosis Worthy of a Tattoo," CMT patient and champion fundraiser Vittorio Ricci describes how he was finally diagnosed after six years and several trips to the CMTA Center of Excellence headed by Dr. Michael Shy.
Accelerate Clinical Trials in Charcot-Marie-Tooth Disease
Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT) This study is
New, Potentially Treatable, Type of CMT Discovered
A team led by Dr. Stephan Züchner at the University of Miami has discovered a new type of Charcot-Marie-Tooth (CMT) disease that may be treatable with drugs already approved for other diseases.
CMT2E Gene Therapy Project Approved
The CMTA Board of Directors approved a $265,000 research project for CMT2E that aims to advance CMT2E gene therapy by demonstrating positive results for axonal forms of CMT affecting motor neurons.
